Global Expansion Is No Longer an Afterthought: What Emerging Biopharma Companies Must Get Right
For emerging biopharma companies, global expansion decisions can shape an asset’s long-term commercial potential well before the first regulatory approval. Evolving pricing policies, country-specific reimbursement requirements and complex evidence expectations are challenging traditional market-entry strategies.
Successful expansion requires companies to work backward from priority markets, aligning clinical development, evidence generation and commercialization planning with the regulatory and reimbursement requirements of each region.
You will learn how to:
- Plan for global expansion early. Align clinical trial design and evidence generation with the regulatory and reimbursement expectations of priority markets
- Rethink market sequencing. Evaluate pricing dynamics, international reference pricing, patient opportunity and competitive conditions to determine where—and whether—to launch
- Build local scientific credibility. Engage medical affairs early to establish relationships, understand unmet needs and inform market readiness
- Anticipate operational complexity. Address regulatory, legal, compliance and supply chain requirements before they create costly launch delays
- Connect strategy across functions. Integrate clinical, medical affairs, market access and commercial expertise to preserve flexibility and maximize asset value
Download the article to explore practical strategies for navigating global market expansion, prioritizing opportunities and aligning evidence, access and commercialization decisions to support successful launches beyond the US.
Related Content
Looking for exclusive insight?
